Yes I agree, it is most likely a partnership. But there arent many other reasons to modify preferred shares. If there is a deal made, it wouldnt be chump change. Most pharmaceutical companies need partnerships or buyout especially after significant trials. AMBS is looking good. I dont see why a company such as ROCHE wouldnt approach them.
Market Data 
Markets 
AI
